SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Care-plan review) — Mary McLeod Bethune

PatientMary McLeod Bethune
Date of birth1953-07-10
IdentifiersMRN HR-ML043-SYN; SSN (made up) 000-43-2195
Document date2026-07-27
AuthorViola Harrington-Mbeki, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Asthma review six weeks after an exacerbation. [S]

History of Present Illness

Mrs. Bethune returns six weeks after the moderate exacerbation that followed a cold, treated at the sick visit with extra budesonide-formoterol, five days of prednisone and a step-up to two maintenance inhalations twice daily. The clinic nurse telephoned her two and seven days later and she was recovering, but she was not seen in person within the week. Since then she has had no night waking and uses the reliever about once a week; she has been to two board meetings in Washington without breathlessness. Her peak flow has been 320 to 345 L/min each morning. She uses the spacer each time and has missed only a few doses. She stopped omeprazole as planned and has had heartburn only once. Home blood pressure averages 126/76. She has had no thoughts of self-harm. [S]

ElementDetail
ExacerbationModerate, with a cold, six weeks ago; prednisone for five days; no emergency visit
Since thenNo night waking; reliever about once a week; peak flow 320 to 345 L/min
TravelTwo meetings in Washington without breathlessness

Review of Systems

SystemResultFinding
RespiratoryNegativeNo night waking or breathlessness on stairs
Ears, nose, mouth, and throatNegativeNose clear; no hoarseness or thrush
GastrointestinalNegativeHeartburn once since stopping omeprazole
CardiovascularNegativeNo ankle swelling or chest pain
PsychiatricNegativeMood good; PHQ-2 0

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 mcg/actuation inhaler, two puffs as needed, from an urgent care visit four months ago (used alone, without an inhaled steroid)Two puffs every 4 hours as needed; she uses it most daysRespiratory tract route2025-11-03 to 2026-03-23completedS
Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning for five days40 mg each morning for five daysOral route2026-06-15 to 2026-06-19completedS
Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a dayOne inhalation twice daily plus one as neededRespiratory tract route2026-03-23 to 2026-06-15completedS
Budesonide-formoterol 160/4.5 mcg inhaler with a spacer: two inhalations twice daily and one as needed (stepped up during the exacerbation), no more than 12 inhalations a dayTwo inhalations twice daily plus one as neededRespiratory tract route2026-06-15 to 2026-07-27completedS
Budesonide-formoterol 160/4.5 mcg inhaler with a spacer: one inhalation twice daily and one as needed, no more than 12 inhalations a dayOne inhalation twice daily plus one as neededRespiratory tract route2026-07-27activeS
Fluticasone propionate 50 mcg/actuation nasal spray, two sprays in each nostril once daily, aimed away from the septumTwo sprays each nostril dailyNasal route2026-03-23activeS
Sodium chloride 0.65% nasal spray, two sprays in each nostril up to four times daily before the steroid sprayTwo sprays each nostril up to four times dailyNasal route2026-03-23activeS
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-23activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-23activeS
Omeprazole 20 mg delayed-release capsule, one capsule daily 30 minutes before breakfast for eight weeksOne capsule daily before breakfastOral route2026-03-23 to 2026-05-18completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-27Body height163cmS
2026-07-27Body weight86.4kgS
2026-07-27Body mass index (BMI) [Ratio]32.5kg/m2S
2026-07-27Systolic blood pressure128mm[Hg]S
2026-07-27Diastolic blood pressure78mm[Hg]S
2026-07-27Heart rate72/minS
2026-07-27Respiratory rate16/minS
2026-07-27Body temperature36.5CelS
2026-07-27Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-27Total score [ACT]22{score}S
2026-07-27FEV1 --pre bronchodilation1.72LLower limit of normal, GLI Global race-neutral equations; predicted 2.03 LNormalS
2026-07-27FEV1 measured/predicted85%GLI Global race-neutral equationsNormalS
2026-07-27FEV1/FVC0.73{ratio}>=0.7NormalS
2026-07-27Fractional concentration of exhaled nitric oxide21[ppb]Above 50 ppb high; 25 to 50 intermediate (ATS)NormalS
2026-07-27Maximum expiratory gas flow Respiratory system airway by Peak flow meter330L/min80 percent of her personal best of 340 L/minNormalS
2026-07-27Hemoglobin [Mass/volume] in Blood13g/dL12-15.5 g/dLNormalS
2026-07-27Leukocytes [#/volume] in Blood by Automated count7.110*3/uL4-11 10*3/uLNormalS
2026-07-27Eosinophils [#/volume] in Blood by Automated count0.2410*3/uL0-0.5 10*3/uLNormalS
2026-07-27Platelets [#/volume] in Blood by Automated count25510*3/uL150-400 10*3/uLNormalS
2026-07-27Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
2026-07-27Creatinine [Mass/volume] in Serum or Plasma0.96mg/dL0.59-1.04 mg/dLNormalS
2026-07-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M62mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-07-27Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Physical Exam

Vital signs recorded on 2026-07-27; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 86.4 kg; blood pressure 128/78, pulse 72; oxygen saturation 97 percent
RespiratoryClear; no wheeze on forced expiration
MouthNo thrush
ExtremitiesNo ankle edema

Problems

ProblemClinical statusVerificationCodeProvenance
Wheeze, cough and breathlessness for four months: waking with cough and tight chest two or three nights a week, breathless on one flight of stairs, relieved by albuterol, worse with colds, dust and strong scents; known asthma for many years but never confirmed by lung function testing and never treated with an inhaled steroid. Asthma, COPD and heart failure to be distinguished: spirometry with bronchodilator response, FeNO and an echocardiogram bookedresolvedconfirmed R06.2S — Synthetic presenting problem anchored to her documented chronic asthma. Superseded by the diagnosis at the second visit.
Blocked nose, thick postnasal drip and a reduced sense of smell for years, worse in the last year; no nosebleeds; never seen by an ear, nose and throat specialistresolvedconfirmed R09.81S — Synthetic upper-airway symptoms; superseded by the diagnosis of chronic rhinosinusitis after nasal endoscopy.
Gastro-esophageal reflux: heartburn and an acid taste two or three evenings a week, worse after late meals and lying down; no trouble swallowing, vomiting, black stools or weight lossactiveconfirmed K21.9S — Synthetic comorbidity of asthma; not a claim about her real health.
Obesity, class 1 (BMI 33.1); she wants to walk more and to keep up with her work, and agreed to talk about itactiveconfirmed E66.811S — Synthetic comorbidity recorded in her words and with her agreement; not a claim about her real weight.
Moderate asthma exacerbation triggered by a cold: two days of worsening wheeze and night waking despite eight reliever inhalations a day, peak flow 205 L/min (60 percent of her best), oxygen saturation 94 percent; improved to 275 L/min in clinic; treated without admission; resolvedresolvedconfirmed J45.41S — Synthetic exacerbation; not a claim about a real attack.
Asthma, confirmed: variable airflow obstruction (FEV1 64 percent predicted, rising 270 mL or 21 percent after bronchodilator, with a normal post-bronchodilator FEV1/FVC of 0.72 and normal DLCO); type 2 inflammation (FeNO 46 ppb, blood eosinophils 0.42 x10^3/uL, total IgE 210, house dust mite sensitization); not COPD and not heart failure. Uncontrolled at diagnosis on albuterol aloneactiveconfirmed J45.40S — Synthetic modern confirmation linked to her documented chronic asthma.
Hypertensive heart disease without heart failure: clinic blood pressure 152/88 and 146/86, home average 144/84; mild concentric left ventricular hypertrophy with grade 1 diastolic dysfunction and a normal ejection fraction (62 percent); BNP 48 pg/mLactiveconfirmed I11.9S — Synthetic finding of the modern work-up; not a claim about her real heart.
Hyperlipidemia: LDL cholesterol 144 mg/dL; 10-year ASCVD risk above 20 percent with hypertensionactiveconfirmed E78.5S — Synthetic cardiovascular risk factor.
Chronic rhinosinusitis without nasal polyps: years of congestion, postnasal drip and reduced smell, with mucosal swelling and mucus in both middle meatuses and no polyps on nasal endoscopyactiveconfirmed J32.9S — Synthetic upper-airway comorbidity of asthma; not a claim about her real health.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyAsthma Control Test, symptoms, night waking and reliever useEvery visitCompleted todayAsthma Control Test 22; reliever about once a week; no night waking
ImagingSpirometry after stabilization and peak flowThree to six months after starting treatment; peak flow daily after an exacerbationCompleted todayFEV1 1.72 L (85 percent), FEV1/FVC 0.73; peak flow 330 L/min (personal best 340)
ImagingFeNO to monitor responseTo monitor anti-inflammatory therapy (NAEPP, conditional)Completed today21 ppb, down from 46
LaboratoryBlood eosinophils for the biologic assessmentAt severe asthma assessment; repeat if lowCompleted today0.24 on inhaled corticosteroid, six weeks after prednisone; white cells 7.1, hemoglobin 13.0, platelets 255
ReferralBiologic assessmentWhen asthma is severe or uncontrolled despite optimized step 4 to 5 treatmentNot indicatedNot severe asthma: well controlled on medium-dose ICS-formoterol with good technique; to be revisited if control is lost or a second oral corticosteroid course is needed within a year
Self-managementReview after an exacerbationWithin one week of any exacerbation (CMID; GINA within one to seven days)DeferredMissed: after the exacerbation at the sick visit the nurse telephoned on days 2 and 7, but no in-person review was booked within a week. No harm resulted: she recovered fully and is well controlled today. Corrective action: the action plan and the clinic's exacerbation order set now book a visit within seven days automatically
ExaminationInhaler technique with her own inhaler, and adherenceEvery visit; before any step-upCompleted todayCorrect with the spacer; few missed doses
Self-managementExacerbation history (oral corticosteroid courses, emergency visits, admissions)Every visitCompleted todayOne moderate exacerbation six weeks ago (one prednisone course this year); no emergency visit or admission
Self-managementStep-up or step-down assessment (GINA track 1)Every visitCompleted todayStepped back down to low-dose maintenance and reliever
Self-managementWritten asthma action planEvery visit and after every exacerbationCompleted todayUpdated with her personal best of 340 L/min after the exacerbation
Self-managementTriggers, exposures and smoking or vapingEvery visitCompleted todayColds the main trigger; vaccines planned for the autumn
ReferralPulmonary rehabilitationFor persistent breathlessness or deconditioningNot indicatedNo persistent breathlessness; walking daily
ExaminationBlood pressure in clinic and at homeEvery visit; home readings at diagnosis and after changesCompleted todayClinic 128/78; home average 126/76: at target
LaboratoryPotassium and kidney functionYearly, or after changesCompleted todayPotassium 4.3, creatinine 0.96, eGFR 62
SurveyDepression screenYearly and as neededCompleted todayPHQ-2 0

Goal progress:

Guideline basis: CMID: Clinical Monitoring Intelligence Database, asthma and hypertension monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023)

Follow-up: Asthma and blood pressure review in three months. Annual wellness visit in about two months, with influenza, COVID-19 and RSV vaccines. Follow the updated action plan. Next scheduled visit 2026-09-21: subsequent annual wellness visit. [S]